The financial terms of the deal were not disclosed. GE Healthcare expects to close the deal in January 2021; its held a minority position in the company since 2017.
Photon-counting CT technology, according to GE Healthcare, could expand the clinical capabilities of traditional CT — providing diagnostic benefits in clinical areas including oncology, cardiology and neurology. PCCT can enable the visualization of minute organ structure details, improved tissue characterization and more accurate material density measurement (or quantification). Plus, the radiation dose is lower.
Created in 2012 out of the KTH Royal Institute of Technology in Stockholm, Prismatic Sensors has patented a novel way to position the silicon sensors “edge-on” so the detector is deep enough to absorb very high energy photons and fast enough to count hundreds of millions of CT photons per second.
“We believe this technology has the potential to be a substantial step forward for CT imaging to establish a new standard of care and eventually improve clinical outcomes for millions of patients worldwide,” GE Healthcare CEO Kieran Murphy said in a news release. “From the first X-ray machines to the first photon-counting CT prototype, GE Healthcare is committed to pioneering next-generation technologies to achieve precision health and improve lives. We are excited about this cutting-edge approach with Deep Silicon and its clinical potential.”
